Bone health in cancer: ESMO Clinical Practice Guidelines
Bone health in cancer: ESMO Clinical Practice Guidelines
复制标题
DOI：
10.1016/j.annonc.2020.07.019
复制
发表时间：
2020-12-01
影响因子：
50.5
通讯作者：
Jordan, K.
中科院分区：
文献类型：
--
作者：
Coleman, R.;Hadji, P.;Jordan, K.
要点许多骨转移患者的晚期癌症的临床病程可以通过最佳的多学科治疗来改变。骨靶向药物显著降低了跨肿瘤类型的骨转移患者的骨骼发病率，应该是标准治疗的一部分。治疗引起的骨丢失增加了骨折的风险，可能需要在改变生活方式的同时使用骨靶向药物。在绝经后早期乳腺癌的标准辅助治疗中加入双膦酸类药物可以减少骨复发并提高存活率。
HighlightsThe clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.